PL370176A1 - Podstawione 1,4-benzodiazepiny i ich zastosowaniedo leczenia raka - Google Patents
Podstawione 1,4-benzodiazepiny i ich zastosowaniedo leczenia rakaInfo
- Publication number
- PL370176A1 PL370176A1 PL02370176A PL37017602A PL370176A1 PL 370176 A1 PL370176 A1 PL 370176A1 PL 02370176 A PL02370176 A PL 02370176A PL 37017602 A PL37017602 A PL 37017602A PL 370176 A1 PL370176 A1 PL 370176A1
- Authority
- PL
- Poland
- Prior art keywords
- sup
- sub
- optionally substituted
- cycloalkyl
- aralkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33123501P | 2001-11-13 | 2001-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL370176A1 true PL370176A1 (pl) | 2005-05-16 |
Family
ID=23293137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL02370176A PL370176A1 (pl) | 2001-11-13 | 2002-11-13 | Podstawione 1,4-benzodiazepiny i ich zastosowaniedo leczenia raka |
Country Status (26)
Country | Link |
---|---|
US (2) | US7067512B2 (pl) |
EP (1) | EP1443937B1 (pl) |
JP (1) | JP4497921B2 (pl) |
KR (1) | KR20050044413A (pl) |
CN (1) | CN1596114A (pl) |
AT (1) | ATE398453T1 (pl) |
AU (1) | AU2002340464B2 (pl) |
BR (1) | BR0214048A (pl) |
CA (1) | CA2466055A1 (pl) |
CY (1) | CY1108352T1 (pl) |
DE (1) | DE60227185D1 (pl) |
DK (1) | DK1443937T3 (pl) |
ES (1) | ES2309209T3 (pl) |
HR (1) | HRP20040415A2 (pl) |
HU (1) | HUP0402003A3 (pl) |
IL (1) | IL161692A0 (pl) |
MX (1) | MXPA04004500A (pl) |
NO (1) | NO20042146L (pl) |
NZ (1) | NZ532463A (pl) |
PL (1) | PL370176A1 (pl) |
PT (1) | PT1443937E (pl) |
RU (1) | RU2004118243A (pl) |
SI (1) | SI1443937T1 (pl) |
UA (1) | UA76798C2 (pl) |
WO (1) | WO2003041715A1 (pl) |
ZA (1) | ZA200403082B (pl) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040197893A1 (en) * | 2002-10-16 | 2004-10-07 | Carsten Schubert | HDM2-inhibitor complexes and uses thereof |
US20050227932A1 (en) * | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
US7655646B2 (en) * | 2003-01-21 | 2010-02-02 | Thallion Pharmaceuticals, Inc. | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals |
US7358241B2 (en) * | 2003-01-21 | 2008-04-15 | Thallion Pharmaceuticals, Inc. | Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions |
US7186713B2 (en) | 2003-01-21 | 2007-03-06 | Ecopia Biosciences, Inc. | Farnesyl dibenzodiazepinones and methods of treating cancer using same |
US7262293B2 (en) * | 2003-07-02 | 2007-08-28 | Corus Pharma | Aztreonam L-lysine and methods for the preparation thereof |
US7572783B2 (en) | 2004-08-13 | 2009-08-11 | Amgen Inc. | Substituted benzofused heterocycles |
DE602005022472D1 (de) | 2004-09-22 | 2010-09-02 | Janssen Pharmaceutica Nv | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
JP2008515395A (ja) * | 2004-09-28 | 2008-05-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 細菌のatp合成酵素の結合ドメイン |
US7763604B2 (en) * | 2005-05-16 | 2010-07-27 | Thallion Pharma Ceuticals, Inc. | Methods for administration of a farnesyl dibenzodiazepinone |
CA2779041A1 (en) * | 2005-11-01 | 2007-05-10 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
JP5385125B2 (ja) | 2006-03-22 | 2014-01-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | MDM2とp53の間の相互作用の阻害剤 |
DE602007007065D1 (de) | 2006-03-22 | 2010-07-22 | Janssen Pharmaceutica Nv | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 |
WO2008014216A1 (en) | 2006-07-28 | 2008-01-31 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
US8470785B2 (en) | 2006-07-28 | 2013-06-25 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
CN101605798A (zh) | 2006-12-14 | 2009-12-16 | 第一三共株式会社 | 咪唑并噻唑衍生物 |
AU2008235212B2 (en) * | 2007-04-09 | 2014-01-16 | Methylgene Inc. | Inhibitors of histone deacetylase |
NZ580801A (en) * | 2007-05-10 | 2012-09-28 | Bristol Myers Squibb Co | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2008144981A1 (fr) * | 2007-05-25 | 2008-12-04 | Topharman Shanghai Co., Ltd. | Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine |
CN107021895A (zh) * | 2007-06-12 | 2017-08-08 | 尔察祯有限公司 | 抗菌剂 |
ES2534899T3 (es) | 2007-08-06 | 2015-04-30 | Janssen Pharmaceutica, N.V. | Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53 |
AR070449A1 (es) * | 2008-02-22 | 2010-04-07 | Otsuka Pharma Co Ltd | Compuesto de benzodiazepina y composicion farmaceutica |
EP2298778A4 (en) | 2008-06-12 | 2011-10-05 | Daiichi Sankyo Co Ltd | IMIDAZOTHIAZOL DERIVATIVE WITH 4,7-DIAZASPIRO [2.5] OCTAN RING STRUCTURE |
KR101730407B1 (ko) | 2009-02-04 | 2017-04-26 | 얀센 파마슈티카 엔.브이. | 항암제로서의 인돌 유도체 |
FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
CN102321034B (zh) * | 2011-06-07 | 2014-08-13 | 中国人民解放军第二军医大学 | 硫代苯二氮卓类化合物及其作为药物的用途 |
TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲hdm2抑制劑之經取代咪唑吡啶 |
CN105693634B (zh) * | 2016-03-17 | 2018-12-11 | 清华大学 | 化合物及其用途 |
WO2017214359A1 (en) * | 2016-06-10 | 2017-12-14 | Venenum Biodesign Llc | Novel clostridium difficile toxin inhibitors |
WO2018138673A1 (en) * | 2017-01-25 | 2018-08-02 | Sorrento Therapeutics, Inc. | Cell penetrating peptide inhibitors of p53-mdm2 interaction |
CN110317294B (zh) * | 2018-03-30 | 2021-06-18 | 长春理工大学 | 一种三苯胺类温敏荧光聚合物及其制备方法 |
CN111995576A (zh) * | 2020-08-31 | 2020-11-27 | 三峡大学 | 多取代含氮杂环化合物的制备方法 |
WO2023174374A1 (zh) * | 2022-03-16 | 2023-09-21 | 江苏恒瑞医药股份有限公司 | 稠杂环类化合物、其制备方法及其在医药上的应用 |
CN117263873A (zh) * | 2022-06-15 | 2023-12-22 | 复旦大学 | 1,4-苯二氮䓬类化合物及其在制备抗肿瘤药物中的用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
US5389631A (en) | 1991-10-29 | 1995-02-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5441952A (en) | 1993-04-05 | 1995-08-15 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
EP0755394A1 (en) | 1994-04-15 | 1997-01-29 | Glaxo Wellcome Inc. | A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds |
US5817751A (en) | 1994-06-23 | 1998-10-06 | Affymax Technologies N.V. | Method for synthesis of diketopiperazine and diketomorpholine derivatives |
DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
US6492553B1 (en) * | 1998-01-29 | 2002-12-10 | Aventis Pharamaceuticals Inc. | Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds |
EP1051397B1 (en) | 1998-01-29 | 2008-12-31 | Aventis Pharmaceuticals Inc. | Method for preparing an n- (aliphatic or aromatic)carbonyl -2-aminoacetamide compound and a cyclyzed compound |
AU3894800A (en) | 1999-03-23 | 2000-10-09 | Axys Pharmaceuticals, Inc. | Solid phase synthesis of benzodiazepine diones |
US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
ATE433752T1 (de) | 1999-04-30 | 2009-07-15 | Univ Michigan | Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis |
WO2001004103A1 (en) | 1999-07-13 | 2001-01-18 | F. Hoffmann-La Roche Ag | Benzazepinones and quinazolines |
US6600016B1 (en) * | 1999-08-24 | 2003-07-29 | Advanced Syntech Llc | Multifunctionalized solid support resins for synthesis of combinatorial libraries and method for using the same |
AU2882801A (en) * | 2000-01-28 | 2001-08-07 | Kaken Pharmaceutical Co., Ltd. | Azepine derivatives |
-
2002
- 2002-11-13 US US10/292,876 patent/US7067512B2/en not_active Expired - Fee Related
- 2002-11-13 AU AU2002340464A patent/AU2002340464B2/en not_active Ceased
- 2002-11-13 HU HU0402003A patent/HUP0402003A3/hu unknown
- 2002-11-13 CA CA002466055A patent/CA2466055A1/en not_active Abandoned
- 2002-11-13 ES ES02778828T patent/ES2309209T3/es not_active Expired - Lifetime
- 2002-11-13 WO PCT/US2002/036208 patent/WO2003041715A1/en not_active Application Discontinuation
- 2002-11-13 DK DK02778828T patent/DK1443937T3/da active
- 2002-11-13 KR KR1020047007168A patent/KR20050044413A/ko not_active Application Discontinuation
- 2002-11-13 PT PT02778828T patent/PT1443937E/pt unknown
- 2002-11-13 DE DE60227185T patent/DE60227185D1/de not_active Expired - Lifetime
- 2002-11-13 RU RU2004118243/04A patent/RU2004118243A/ru not_active Application Discontinuation
- 2002-11-13 CN CNA028239156A patent/CN1596114A/zh active Pending
- 2002-11-13 AT AT02778828T patent/ATE398453T1/de active
- 2002-11-13 IL IL16169202A patent/IL161692A0/xx unknown
- 2002-11-13 JP JP2003543602A patent/JP4497921B2/ja not_active Expired - Fee Related
- 2002-11-13 BR BR0214048-9A patent/BR0214048A/pt not_active IP Right Cessation
- 2002-11-13 PL PL02370176A patent/PL370176A1/pl not_active Application Discontinuation
- 2002-11-13 UA UA20040604569A patent/UA76798C2/uk unknown
- 2002-11-13 SI SI200230733T patent/SI1443937T1/sl unknown
- 2002-11-13 MX MXPA04004500A patent/MXPA04004500A/es active IP Right Grant
- 2002-11-13 EP EP02778828A patent/EP1443937B1/en not_active Expired - Lifetime
- 2002-11-13 NZ NZ532463A patent/NZ532463A/en not_active IP Right Cessation
-
2004
- 2004-04-22 ZA ZA200403082A patent/ZA200403082B/en unknown
- 2004-05-07 HR HR20040415A patent/HRP20040415A2/hr not_active Application Discontinuation
- 2004-05-25 NO NO20042146A patent/NO20042146L/no not_active Application Discontinuation
-
2006
- 2006-03-09 US US11/371,964 patent/US20060148792A1/en not_active Abandoned
-
2008
- 2008-09-17 CY CY20081101010T patent/CY1108352T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1443937B1 (en) | 2008-06-18 |
ES2309209T3 (es) | 2008-12-16 |
EP1443937A1 (en) | 2004-08-11 |
WO2003041715A1 (en) | 2003-05-22 |
JP2005509005A (ja) | 2005-04-07 |
MXPA04004500A (es) | 2004-08-11 |
AU2002340464B2 (en) | 2008-03-13 |
PT1443937E (pt) | 2008-09-23 |
CY1108352T1 (el) | 2014-02-12 |
NZ532463A (en) | 2007-02-23 |
DK1443937T3 (da) | 2008-10-20 |
US20060148792A1 (en) | 2006-07-06 |
DE60227185D1 (de) | 2008-07-31 |
IL161692A0 (en) | 2004-09-27 |
ATE398453T1 (de) | 2008-07-15 |
BR0214048A (pt) | 2004-10-13 |
HUP0402003A2 (hu) | 2005-02-28 |
KR20050044413A (ko) | 2005-05-12 |
US20030109518A1 (en) | 2003-06-12 |
SI1443937T1 (sl) | 2009-02-28 |
HRP20040415A2 (en) | 2005-04-30 |
JP4497921B2 (ja) | 2010-07-07 |
ZA200403082B (en) | 2005-04-22 |
US7067512B2 (en) | 2006-06-27 |
HUP0402003A3 (en) | 2005-06-28 |
NO20042146L (no) | 2004-08-11 |
UA76798C2 (uk) | 2006-09-15 |
CN1596114A (zh) | 2005-03-16 |
CA2466055A1 (en) | 2003-05-22 |
RU2004118243A (ru) | 2006-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1443937T1 (sl) | Substituirani 1,4-benzodiazepini in njihove uporabe za zdravljenje raka | |
WO2004010949A3 (en) | Compounds active in spinigosine 1-phosphate signaling | |
SI1678166T1 (sl) | Inhibitorji proteinske kinaze | |
PL1635835T3 (pl) | Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF | |
MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
MY131019A (en) | Tropane derivatives useful in therapy | |
WO2005044192A3 (en) | Triazole compounds and uses related thereto | |
WO2002072009A3 (en) | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | |
CA2469592A1 (en) | Hiv integrase inhibitors | |
NZ331801A (en) | Therapeutic agent for diabetes | |
JP2007517007A5 (pl) | ||
DE602004020730D1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
MY133527A (en) | Isoquinoline derivatives | |
BR0311960A (pt) | Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica | |
MXPA05008706A (es) | 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas. | |
NO20060277L (no) | Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger | |
TW200505438A (en) | Method of treating cancer with azaspirane compositions | |
MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
WO2007001839A3 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
ZA200703275B (en) | 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinollnecarbonitriles for the treatment of ischemic Injury | |
EP1344777A4 (en) | IMIDAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR APPLICATION | |
SI1735274T1 (sl) | Nepeptidni inhibitorji matriksnih metaloproteinaz | |
MY139608A (en) | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity | |
WO2003103599A3 (en) | CASPASE-1 INHIBITORS AND METHODS OF USE | |
WO2023245015A3 (en) | Phenyl amide compounds and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |